On Friday shares of Contango Oil & Gas Company (NYSEMKT:MCF) closed at $20.88. Contango Oil & Gas Company (NYSE MKT: MCF) announced it expects to issue its first quarter 2015 earnings press release, including an operational update, before the market opens on Monday, May 11, 2015. In conjunction with the release, Contango will conduct a conference call to discuss the contents of that release on Monday, May 11, 2015 at 9:30am Central Daylight Time.
Tantech Holdings Ltd (NASDAQ:TANH) in last trading activity fell -1.82% to close at $12.41. Tantech Holdings Ltd (NASDAQ:TANH) is -22.00% away from its 52 week high.
On last trading day ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) increased 1.09% to close at $0.46. Its volatility for the week is 3.95% while volatility for the month is 6.27%. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) monthly performance is 4.80%. On May 5, ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) announced that Andrew Gengos, President and Chief Executive Officer, will present live at VirtualInvestorConferences.com on May 7, 2015. This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
On last trading day Nevsun Resources Ltd. (NYSEMKT:NSU) fell -0.49% to close at $4.03. Its volatility for the week is 3.40% while volatility for the month is 3.55%.Nevsun Resources Ltd. (NYSEMKT:NSU) monthly performance is 20.66%. On May 7, Shares of Nevsun Resources (TSE:NSU) have earned an average rating of “Hold” from the six analysts that are covering the stock. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is C$5.95.
On Friday shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) closed at $9.11. Company’s sales growth for last 5 years was 66.20% and EPS growth for next 5 years is recorded as 41.40%. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2015, including revenue from sales of Iclusig® (ponatinib). The Company also provided an update on corporate developments. Net product revenues from sales of Iclusig were $23.9 million for the quarter ended March 31, 2015, an increase of 12% versus the fourth quarter of 2014.